Alamar Biosciences Q3 Net Loss Widens 66% to $13.3 Million
Q3 2026 revenue rose 68% year over year to $33.5 million.
Related stories
Ivanhoe Mines Reports 2026 Third-Quarter Financial Results
M impact | EQUITY | Nov 03, 2026, 11:27 PM UTC
Everus Construction Group Reports Quarterly Results
Everus Construction Group reported results for the quarter ended September 30. The supplied text does not include the figures.
M impact | EQUITY | Nov 03, 2026, 11:25 PM UTC
One New Firm to Keep CVS Health Name, Run by David Joyner
CVS said one of the two new firms will retain the CVS Health name and be led by David Joyner, the CEO of the current CVS.
L impact | EQUITY | Nov 03, 2026, 11:24 PM UTC
Block Raises Full-Year Profit Forecast
Block raised its full-year profit forecast, citing Cash App growth in the third quarter.
M impact | EQUITY | Nov 03, 2026, 11:24 PM UTC
CCU Reports Improved Quarterly Results, but 2026 Earnings Still Fall
CCU’s quarterly results improved, while its earnings continued to decline on a cumulative basis in 2026.
M impact | EQUITY | Nov 03, 2026, 11:24 PM UTC
LTC Properties Reports Quarterly Results Through September 30
LSEG's machine-generated summary covers the quarter ended September 30; the supplied text includes no financial results.
M impact | EQUITY | Nov 03, 2026, 11:22 PM UTC